Cerenome, Inc. (CNSY) Stock Analysis & Investment Frameworks
Cerenome, Inc. (CNSY) stock analysis on Invetso. Review Cerenome, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Cerenome, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Medical - Pharmaceuticals
- Country: US
Cerenome, Inc. Key Financial Metrics
- Market Cap: $12.90M
- Revenue: $5.21M
- ROE: -394.17%
- ROIC: -479.39%
- Dividend Yield: N/A
About Cerenome, Inc.
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
Cerenome, Inc. Investment Frameworks
Invetso analyzes Cerenome, Inc. (CNSY) across the following frameworks:
- Cerenome, Inc. 10Y Growth Potential
- Cerenome, Inc. Scenario Analysis
- Cerenome, Inc. Risks & Opportunities
- Cerenome, Inc. Economic Moat
- Cerenome, Inc. Business Model
- Cerenome, Inc. Management
- Cerenome, Inc. SWOT Analysis
- Cerenome, Inc. Porter's 5 Forces
- Cerenome, Inc. PESTLE Analysis
- Cerenome, Inc. ESG Analysis